Morcamilast vs Mufemilast

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

Morcamilast

Developed by Meiji Seika Pharma and partners

Phase 2 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Mufemilast

Marketed by Tianjin Hemay Pharmaceutical

Phase 3 in Psoriasissmall molecule
Partial signal

NCT04839328 · Phase 3 · completed

The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75). (week 16): PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) (met)

Result source: NCT04839328

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMorcamilastMufemilast
PASI 75—Not reported—Not posted · NCT04839328
PASI 90—Not reported—Not posted · NCT04839328
PASI 100—Not reported—Not posted · NCT04839328
sPGA 0/1—Not reported—Not posted · NCT04839328
DLQI, change—Not reported—Not posted · NCT04839328

PASI 75

Morcamilast
—Not reported
Mufemilast
—Not posted · NCT04839328

PASI 90

Morcamilast
—Not reported
Mufemilast
—Not posted · NCT04839328

PASI 100

Morcamilast
—Not reported
Mufemilast
—Not posted · NCT04839328

sPGA 0/1

Morcamilast
—Not reported
Mufemilast
—Not posted · NCT04839328

DLQI, change

Morcamilast
—Not reported
Mufemilast
—Not posted · NCT04839328
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Morcamilast: registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mufemilast
PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) NCT04839328 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Morcamilast's landscape · Mufemilast's landscape